EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-dose phase I-II trial of E-7869 in prostate cancer patients Safety and time to PSA progression



Multi-dose phase I-II trial of E-7869 in prostate cancer patients Safety and time to PSA progression



Proceedings of the American Association for Cancer Research Annual Meeting 42: 142, March




(PDF 0-2 workdays service: $29.90)

Accession: 035349135

Download citation: RISBibTeXText



Related references

Multi-dose Phase IIa trial of MPC-7869 in prostate cancer patients with increasing prostate specific antigen. Proceedings of the American Association for Cancer Research Annual Meeting 43: 749, March, 2002

PK guided multi-dose, tolerance and safety of E-7869 in prostate cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting (41): 609, March, 2000

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet. Oncology 15(9): 975-985, 2014

Re: activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. European Urology 67(2): 348-349, 2015

The short-term safety and immune responses of HER-2 DNA AutoVacTM in patients with HER-2 positive metastatic breast cancer Results from the first dose level of the phase I multi-dose trial. Breast Cancer Research & Treatment 76(Supplement 1): S80, December, 2002

E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Research 60(8): 2203-2208, 2000

Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: results of a multi-institutional phase II trial. RadioTherapy and Oncology 106(2): 215-219, 2013

A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62(2): 115-122, 2004

Satraplatin increases progression-free survival (PFS) and delays pain progression in hormone refractory prostate cancer (HRPC): Results of SPARC, an international phase III trial with 950 patients. 2007

Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. International Journal of Radiation Oncology, Biology, Physics 84(4): E483-E490, 2013

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet. Oncology 13(5): 509-517, 2012

Results of the feasibility stage of STAMPEDE: a Multi-Arm, Multi-Stage phase II/III trial in patients with high risk prostate cancer (MRC PR08, ISRCTN78818544). 2007

Increased time to progression and sustained PSA velocity responses in a phase II trial in advanced metastatic prostate cancer following treatment with ONY-P1, an allogeneic whole cell vaccine. Journal of Clinical Oncology 23(16_suppl): 4726-4726, 2016

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunology, ImmunoTherapy 59(7): 1001-1009, 2010

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time. Bmc Cancer 13(): 613-613, 2014